Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Soligenix Inc. Stories

2013-05-03 08:25:23

PRINCETON, N.J., May 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today its financial results for the quarter ended March 31, 2013. Soligenix's revenues for the quarter ended March 31, 2013 were $0.9 million as compared to $0.6 million for the first quarter of 2012....

2013-05-01 08:30:52

Soligenix to Expand Biodefense and Infectious Disease Product Pipeline PRINCETON, N.J. and GERMANTOWN, Md., May 1, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today it will jointly develop a treatment for Melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic...

2013-04-16 08:28:30

Presentation on April 18, 2013 PRINCETON, N.J., April 16, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products for serious inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the stockpiling of biodefense vaccines - technology...

2013-03-27 08:31:27

PRINCETON, N.J., March 27, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients. Clearance of the IND allows Soligenix to initiate a Phase 2,...

2013-03-19 08:26:31

Research Conducted under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., March 19, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today key progress in the development of ThermoVax(TM), its proprietary vaccine thermostabilization technology. Several complementary preclinical studies have indicated the potential for high temperature stability for a minimum of six months and increased potency of...

2013-02-26 08:28:26

PRINCETON, N.J., Feb. 26, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the year ended December 31, 2012. Soligenix's revenues for the year ended December 31, 2012 were $3.1 million as compared to $7.6 million for the prior year. The decrease in revenues was a result of $5.0 million received in 2011 from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) for rights to...

2013-02-20 08:28:05

PRINCETON, N.J., Feb. 20, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today submission of a full contract proposal to the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures. This submission supports a potential multi-year, multi-million dollar contract to develop OrbeShield(TM) (oral beclomethasone...

2013-02-08 08:25:24

PRINCETON, N.J., Feb. 8, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 2013 BIO CEO & Investor Conference on Tuesday, February 12, at 3:00 PM Eastern Standard Time. The presentation will take place in the Duke of Windsor Room at the Waldorf Astoria Hotel in New York City. The...

2013-02-04 08:25:21

PRINCETON, N.J., Feb. 4, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development-stage biopharmaceutical company, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the development of SGX942 for the treatment of oral mucositis, a common complication of cancer treatments. Comprised of cancer supportive care thought leaders with extensive experience in oral mucositis,...

2013-01-29 08:29:39

PRINCETON, N.J., Jan. 29, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that its OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or oral BDP) development program for the treatment of GI ARS has received "Fast Track" designation from the U.S. Food and Drug Administration (FDA). Soligenix has also previously received Orphan Drug designation from the FDA for oral BDP for the prevention of death...